$EIDX: Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in …

Date: Saturday, November 10th, 2018

Stock(s) mentioned:

Source: Benzinga (https://www.benzinga.com)

Summary: 10, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (NASDAQ:EIDX), today announced positive results of its Phase 2 clinical trial studying AG10 …

Full article address: https://www.benzinga.com/pressreleases/18/11/g12675610/eidos-therapeutics-announces-positive-phase-2-data-for-ag10-in-symptom

Related News:

$EIDX $MNK: Key events next week – healthcare

$EIDX: Eidos Therapeutics Receives Positive Opinion for Orphan …

$EIDX: Eidos Therapeutics to Present Phase 2 Data for AG10 in TTR …

$EIDX: FDA Grants Orphan Drug Designation to Eidos Therapeutics …

$PFE $ALNY $IONS $AKCA $EIDX $SPX: Pfizer stock drops 2% as positive rare-disease drug results won’t stop competitors

Latest News:

$SFIX: Stitch Fix Stumbles Again

$CBSA: CBS Directors Fear Legal Risks from Leaks in Moonves Probe

$ARLO: Bragar Eagel & Squire, PC is Investigating Arlo Technologies, Inc …

$SPPI: Here’s Why Spectrum Pharmaceuticals Rose 21.5% in November

$IIVI: Why Finisar Shares Rose 40% Last Month

$CIVI: Civitas Solutions, Inc. Announces Date of Annual Meeting of …

$HSBA.LN: Huawei CFO Case Hinges on an Offshore Puzzle

$CWH: Why Camping World Holdings Stock Jumped 10% in November

$PNC: 4 Stocks Billionaire Warren Buffett and Insiders Love (and 1 They …

$ZUO $HD $LOW $AMD $AAXN $PFG: AMD, Cisco, Home Depot and Axon: ‘Mad Money’ Lightning Round

$ASNA: Ascena Retail Group Inc (ASNA) CEO David Jaffe on Q1 2019 …